Management Of Premenopausal Hr+/Her2- Breast Cancer With Micro-Metastasis

Management of premenopausal HR+/HER2- breast cancer with micro-metastasis

Treatment de-escalation in premenopausal patients with HR+/HER2- breast cancer and micro-metastasis

How to use endocrine therapy in premenopausal women with ER+ metastatic breast cancer

European Society for Medical Oncology (ESMO)

Developing novel guidelines for breast cancer with lymph node micro-metastasis

Conceptualizing Guidelines to Manage Patients with HR–Positive, HER2-Negative Early Breast Cancer

Adjuvant Therapy | 2023 Best of Breast Conference

Total Health | Oncology

Management of axilla after neo-adjuvant treatment

Sequencing Treatment Options in HER2 Positive Breast Cancer: 2023 Best of Breast Conference

Total Health | Oncology

Metastatic HER2 Negative Breast Cancer: Emerging Novel Treatment Strategies

Total Health | Oncology

ASCO 2023 Expert Report in HR positive, HER2 negative breast cancer by Catherine Harper-Wynne

European Society for Medical Oncology (ESMO)

Dr. Hershman on the Use of Endocrine Therapy in Premenopausal HR+/HER2- Breast Cancer

Important considerations in the management of HR+, HER2-negative early breast cancer

How to select treatment for HER2+ breast cancer patients with brain metastasis?

European Society for Medical Oncology (ESMO)

Management of HER2 positive metastatic breast cancer treatment algorithm

Unmet needs and CDK4/6 inhibitors in HR+/HER2- early breast cancer

Which Metastatic Breast Cancer Treatment Is Right for You? What You Need to Know

Patient Empowerment Network

Current state of CDK4/6 inhibitors in metastatic HER2-negative breast cancer

Treatment updates for breast cancer with brain metastases

Treatment Updated for HER2 Positive Breast Cancer: Changing Paradigms

Total Health | Oncology

Optimizing treatment in patients with early-stage HER2-positive breast cancer